Shares of UnitedHealth Group (UNH) finished more than 22% lower Thursday in the stock's 澳洲幸运5官方开奖结果体彩网:worst day in over 25 years after the health-care giant's first-quarter results fell short of analysts' estimates and it cut its profit forecasts for 2025.
UnitedHealth reported adjusted 澳洲幸运5官方开奖结果体彩网:earnings per share (EPS) of $7.20 on revenue that rose 10% year-over-year to $109.58 billion. Analysts polled by Visible 🐬Alpha had expect😼ed $7.25 and $111.46 billion, respectively.
The Eden Prairie, Minnesota-based company lowered its 2025 EPS outlook to a range of $24.65 to $25.15 and its adjusted EPS projection to $26 to $26.50. 澳洲幸运5官方开奖结果体彩网:Last quarter, UnitedHealth said it expected to generate full-year EPS of $28.꧑15 to $28.65 and adjusted EPS from $29.50 to $30.
UnitedHealth attributed the outlook cuts to "heightened care activity indications" in its 澳洲幸运5官方开奖结果体彩网:Medicare Advantage business, and "unanticipated changes in the profile of Optum Health members impacting plannedܫ 2025 reimbursement."
Analysts have said rising medical costs and lower government reimbursements for Medicare Advantage claims mean higher expenses for insurers that operate those plans like UnitedHealth, CNBC reported.
As UnitedHealth shares closed Thursday with their fourth-worst performance since the company went public in 1984, shares of other health insurers like CVS Health (CVS), Humana (HUM), Elevance Health (ELV), and Centene (CNC) also were dragged lower Thursday bജy the cost concerns.
CEO Says UnitedHealth 'Did Not Perform Up to Our Expectations'
CEO Andrew Witty said the company "did not perform up to our expectations, and we are aggressively addressing those challenges to position us well for the years ahead."
UnitedHealth shares entered the day up about 16% since the start of the year, recovering from a February slump 澳洲幸运5官方开奖结果体彩网:following a report that the U.S. Department of Justice wꩲas investigating the company's diagnosing practices.
UPDATE—This article has been updated with the latest share price information and analysis.